Additionally, paste this code immediately after the opening tag:

Intraoperative Astigmatism Management

Innovation Can Take Cataract Surgery to New Levels

Precision is crucial to Astigmatism Management at the time of cataract surgery. It takes thorough planning and precise execution to maximize the benefits of toric IOLs.1 Without it:

  • Pre-op planning can be complex and difficult to access in the OR.
  • Tracking and analyzing surgical patterns to optimize outcomes can be time-consuming.

Do You Have All the Data to Make Informed
Surgical Decisions?

A study has found that, using traditional methods, 55% of cataract refractive surgeries hit ± 0.5 D of their refractive targets.2 Intraoperative diagnostics can boost the success rate, improving your ability to more accurately predict and enhance your toric outcomes — before a patient leaves the OR.

  • Empowered decision-making
  • Streamlined surgical process and guidance
  • Instantaneous refractive data verification
  • Data tracking to help optimize future procedures

The Cataract Refractive Suite by Alcon

The most advanced technologies for every phase of the cataract procedure:

  • Streamlines surgical planning
  • Identifies and addresses potential sources of refractive error during surgery
  • Boosts consistency in hitting cataract refractive targets
  • Designed and integrated to help enhance procedures

AcrySof® IQ 
Toric IOLs

AcrySof® IQ 
Toric IOLs

ORA SYSTEM® 
with VerifEye®+

ORA SYSTEM® 
with VerifEye®+

The Cataract
Refractive Suite

The Cataract
Refractive Suite

  1. Hoffmann PC, Auel S, Hütz WW. Results of higher power toric intraocular lens implantation. J Cataract Refract Surg. 2011;37(8):1411-1418.
  2. Behndig A, Montan P, Stenevi U, Kugelberg M, Zetterström C, Lundström M. Aiming for emmetropia after cataract surgery: Swedish National Cataract Register study. J Cataract Refract Surg. 2012;38(7):1181-1186. 

VIEW IMPORTANT PRODUCT INFORMATION FOR:

ACRYSOF® IQ TORIC INTRAOCULAR LENSES IMPORTANT PRODUCT INFORMATION

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.

INDICATIONS: The AcrySof® IQ Toric posterior chamber intraocular lenses are intended for primary implantation in the capsular bag of the eye for visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens in adult patients with or without presbyopia, who desire improved uncorrected distance vision, reduction of residual refractive cylinder and increased spectacle independence for distance vision.

 

WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Toric IOLs should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary lens repositioning should occur as early as possible prior to lens encapsulation. All viscoelastics should be removed from both the anterior and posterior sides of the lens; residual viscoelastics may allow the lens to rotate.

Optical theory suggests that high astigmatic patients (i.e., > 2.5 D) may experience spatial distortions. Possible toric IOL related factors may include residual cylindrical error or axis misalignments. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon for this product informing them of possible risks and benefits associated with the AcrySof® IQ Toric Cylinder Power IOLs.

Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof® Natural IOL and normal color vision. The effect on vision of the AcrySof® Natural IOL in subjects with hereditary color vision defects and acquired color vision defects secondary to ocular disease (e.g., glaucoma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS® or BSS PLUS® Sterile Intraocular Irrigating Solutions.

ATTENTION: Reference the Directions for Use labeling for a complete listing of indications, warnings and precautions.

ORA SYSTEM® IMPORTANT PRODUCT INFORMATION

CAUTION: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

INTENDED USE: The ORA SYSTEM® uses wavefront aberrometry data in the measurement and analysis of the refractive power of the eye (i.e., sphere, cylinder and axis measurements) to support cataract surgical procedures.

CONTRAINDICATIONS: The ORA SYSTEM® is contraindicated for patients:

  • who have progressive retinal pathology such as diabetic retinopathy, macular degeneration or any other pathology that the physician deems would interfere with patient fixation;
  • who have corneal pathology such as Fuchs’, EBMD, keratoconus, advanced pterygium impairing the cornea or any other pathology that the physician deems would interfere with the measurement process;
  • whose preoperative regimen includes residual viscous substances left on the corneal surface such as lidocaine gel or viscoelastics;
  • with visually significant media opacity (such as prominent floaters or asteroid hyalosis) that will either limit or prohibit the measurement process; or
  • who have received retro or peribulbar block or any other treatment that impairs their ability to visualize the fixation light.

In addition, utilization of iris hooks during an ORA SYSTEM® image capture is contraindicated, because the use of iris hooks will yield inaccurate measurements.

WARNINGS AND PRECAUTIONS:

  • Significant central corneal irregularities resulting in higher order aberrations might yield inaccurate refractive measurements.
  • Post refractive keratectomy eyes might yield inaccurate refractive measurement.
  • The safety and effectiveness of using the data from the ORA SYSTEM® have not been established for determining treatments involving higher order aberrations of the eye such as coma and spherical aberrations.
  • The ORA SYSTEM® is intended for use by qualified health personnel only. 
  • Improper use of this device may result in exposure to dangerous voltage or hazardous laser-like radiation exposure. 
  • Do not operate the ORA SYSTEM® in the presence of flammable anesthetics or volatile solvents such as alcohol or benzene, or in locations that present an explosion hazard.

ATTENTION: Refer to the ORA SYSTEM® Operator’s Manual for a complete description of proper use and maintenance of the ORA SYSTEM®, as well as a complete list of contraindications, warnings and precautions.